AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12007950 — intervention group
Group type: COMPARATOR
Intervention: 16 Gy in 2 fractions on alternate days (8 Gy per fraction, Group B)
Number of subjects: 232
Study 12025819 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-start polymerization
Number of subjects: 30
Study 12025819 — intervention group
Group type: COMPARATOR
Intervention: High-intensity halogen light
Number of subjects: 30
Study 9790491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 2
Study 9790491 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler forms of CBT
Number of subjects: 2
Study 9790491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual CBT administered by a skilled therapist
Number of subjects: 2
Study 7628649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration in Primary Health Care
Number of subjects: 0
Study 2562096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine (pH = 5.38 +/‐ 0.05)
Number of subjects: 52
Study 2562096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine pH‐adjusted with 1.4% sodium bicarbonate (pH = 6.87 +/‐ 0.01)
Number of subjects: 52
Study 2562096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine (pH = 4.80 +/‐ 0.04)
Number of subjects: 52
Study 2562096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine pH‐adjusted with 1:200,000 epinephrine (pH = 6.68 +/‐ 0.01)
Number of subjects: 52
Study 2562096 — intervention group
Group type: COMPARATOR
Intervention: All groups (including alkalinized solutions)
Number of subjects: 52
Study 773481 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction wound drainage
Number of subjects: 51
Study 773481 — intervention group
Group type: COMPARATOR
Intervention: Corrugated wound drainage
Number of subjects: 51
Study 31481106 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (maximum of 2.5 mg three times daily)
Number of subjects: 17
Study 31481106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28820780 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (1‐h bolus of 0.05 µg/min followed by a constant infusion of 0.025 µg/min)
Number of subjects: 104
Study 28820780 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy (control group)
Number of subjects: 104
Study 28820780 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 104
Study 25962863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve calcifications present (n=657)
Number of subjects: 3111
Study 25962863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve/annulus calcifications present (n=85)
Number of subjects: 3111
Study 25962863 — intervention group
Group type: COMPARATOR
Intervention: Basic model including age, pack-years, current smoking status, coronary and aorta calcium volume
Number of subjects: 3111
Study 23238071 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival limbal autograft (AGCL)
Number of subjects: 60
Study 23238071 — intervention group
Group type: COMPARATOR
Intervention: Simple excision with intraoperative mitomycin C (MMC)
Number of subjects: 60
Study 21517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (STDP)
Number of subjects: 0
Study 21517190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 19454870 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 400 mg/d
Number of subjects: 0
Study 19454870 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 200 mg/d
Number of subjects: 0
Study 19454870 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 600 mg/d
Number of subjects: 0
Study 19454870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16778710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg/day for 7 days
Number of subjects: 13
Study 16778710 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 7 days
Number of subjects: 13
Study 15342446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current hormone replacement therapy (HRT) users
Number of subjects: 1271
Study 15342446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-users of hormone replacement therapy (HRT)
Number of subjects: 1271
Study 15342446 — intervention group
Group type: EXPERIMENTAL
Intervention: Never users of hormone replacement therapy (HRT)
Number of subjects: 1271
Study 15342446 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1271
Study 15342446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current HRT use
Number of subjects: 1271
Study 11777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary-negative affect subtype (33%)
Number of subjects: 101
Study 11777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure dietary subtype (67%)
Number of subjects: 101
Study 11777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-analytic subtyping at 2 time points (73 patients)
Number of subjects: 101
Study 11777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative subtyping approaches (by major depression or binge eating frequency)
Number of subjects: 101
Study 9297650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannin‐fluoride preparation
Number of subjects: 31
Study 9297650 — intervention group
Group type: COMPARATOR
Intervention: Conventional autopolymerizing resin
Number of subjects: 31
Study 9297650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 8339574 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional surface-landmark guidance with a 30‐cm catheter
Number of subjects: 162
Study 8339574 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial electrocardiography-guided technique with a 20‐cm central venous catheter
Number of subjects: 162
Study 8339574 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques with a 30‐cm catheter
Number of subjects: 162
Study 2942167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 120 micrograms delivered by a metered dose inhaler (MDI)
Number of subjects: 32
Study 2942167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 125 micrograms delivered by a gas driven nebulizer
Number of subjects: 32
Study 2942167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 500 micrograms delivered by a gas driven nebulizer
Number of subjects: 32
Study 2942167 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 32
Study 31460693 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 69
Study 31175874 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR with coagulation
Number of subjects: 569
Study 31175874 — intervention group
Group type: COMPARATOR
Intervention: EMR (control)
Number of subjects: 569
Study 27026339 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) 15.6, 31.25, 62.5, 125, and 250 mcg once daily; 15.6 and 31.25 mcg twice daily
Number of subjects: 128
Study 27026339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 26293451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren add-on therapy to ARB
Number of subjects: 83
Study 26293451 — intervention group
Group type: COMPARATOR
Intervention: Control group (ARB only)
Number of subjects: 83
Study 24131073 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-millisecond pulse duration and 9 J/cm²
Number of subjects: 40
Study 24131073 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45-millisecond pulse duration and 6 J/cm²
Number of subjects: 40
Study 21529970 — intervention group
Group type: EXPERIMENTAL
Intervention: SST using VR role‐playing (SST‐VR)
Number of subjects: 91
Study 21529970 — intervention group
Group type: COMPARATOR
Intervention: SST using traditional role‐playing (SST‐TR)
Number of subjects: 91
Study 19886395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish diet
Number of subjects: 25
Study 19886395 — intervention group
Group type: COMPARATOR
Intervention: Red meat diet
Number of subjects: 25
Study 17056122 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (500-1500 mg/day)
Number of subjects: 21
Study 17056122 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-15.0 mg/day)
Number of subjects: 21
Study 16083201 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated traction with routine conservative treatment
Number of subjects: 120
Study 16083201 — intervention group
Group type: COMPARATOR
Intervention: Sham traction with routine conservative treatment
Number of subjects: 120
Study 11491207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl 30 mg once daily
Number of subjects: 197
Study 11491207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 9923260 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-barrier product
Number of subjects: 12
Study 9923260 — intervention group
Group type: COMPARATOR
Intervention: Peri-Care
Number of subjects: 12
Study 9923260 — intervention group
Group type: COMPARATOR
Intervention: Double-Guard
Number of subjects: 12
Study 7846219 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (14 mg)
Number of subjects: 3
Study 7846219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (2 mg)
Number of subjects: 3
Study 7846219 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 3
Study 3293415 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol combined with cholestyramine and dietary management
Number of subjects: 0
Study 3293415 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with cholestyramine and dietary management
Number of subjects: 0
Study 30475960 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple flavanol extract (70 mg monomeric flavanols, 65 mg PCs)
Number of subjects: 42
Study 30475960 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of apple flavanol extract (140 mg monomeric flavanols, 130 mg PCs)
Number of subjects: 42
Study 30475960 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple PC extract (130 mg PCs, 6.5 mg monomeric flavanols)
Number of subjects: 42
Study 30475960 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 42
Study 28331914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 0
Study 25434501 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg/min loading for 1 minute, then 0.04 mg/kg/min for 10 minutes)
Number of subjects: 240
Study 25434501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25434501 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 240
Study 23916188 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious mental illness (SMI)
Number of subjects: 163
Study 23916188 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious mental illness (SMI) - African Americans
Number of subjects: 163
Study 23916188 — intervention group
Group type: COMPARATOR
Intervention: General U.S. population - African Americans
Number of subjects: 163
Study 23916188 — intervention group
Group type: COMPARATOR
Intervention: General U.S. population
Number of subjects: 163
Study 20055762 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular approach (IC)
Number of subjects: 80
Study 20055762 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach (AX)
Number of subjects: 80
Study 18205960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (loading dose of 1 microg kg(‐1) for 10 min followed by a maintenance infusion of 0.4 microg kg(‐1) h(‐1))
Number of subjects: 90
Study 18205960 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 90
Study 18205960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 90
Study 17181885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling and food products
Number of subjects: 209
Study 14526957 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotopes as tracers for ruthenium
Number of subjects: 6
Study 14526957 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotopes as tracers for zirconium
Number of subjects: 6
Study 11064784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge hospital at home service (CHAH)
Number of subjects: 229
Study 11064784 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 229
Study 8836934 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg)
Number of subjects: 12
Study 8836934 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with entacapone (400 mg)
Number of subjects: 12
Study 8836934 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (LD) and carbidopa (300 mg and 75 mg respectively) with placebo
Number of subjects: 12
Study 1307270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 60
Study 1307270 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 60
Study 2934785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 2634
Study 2934785 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 2634
Study 30652941 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (sertraline)
Number of subjects: 278
Study 30652941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 29806132 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg capsules, total: 1,000 mg twice daily for 12 weeks)
Number of subjects: 68
Study 29806132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26497665 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy plus cognitive behavioural therapy
Number of subjects: 61
Study 26497665 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study 24559684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block
Number of subjects: 100
Study 24559684 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior local anesthetic infiltration
Number of subjects: 100
Study 24559684 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 22104388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric emergency medicine (PEM) physicians
Number of subjects: 1000
Study 22104388 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medicine (EM) physicians
Number of subjects: 1000
Study 22104388 — intervention group
Group type: COMPARATOR
Intervention: Overall emergency physicians
Number of subjects: 1000
Study 20634175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus colesevelam
Number of subjects: 286
Study 20634175 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 286
Study 17624174 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibra
Number of subjects: 200
Study 17624174 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo Cement Plus
Number of subjects: 200
Study 17624174 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 200
Study 17624174 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 200
Study 17624174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersalloy (bonded with different intermediates)
Number of subjects: 200
Study 17624174 — intervention group
Group type: COMPARATOR
Intervention: Non-bonded amalgams
Number of subjects: 200
Study 15288705 — intervention group
Group type: COMPARATOR
Intervention: Control boys
Number of subjects: 52
Study 15288705 — intervention group
Group type: COMPARATOR
Intervention: Control girls
Number of subjects: 52
Study 15288705 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner Syndrome girls
Number of subjects: 52
Study 11413004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation to rightward optical deviation (3 min duration)
Number of subjects: 15
Study 11413004 — intervention group
Group type: COMPARATOR
Intervention: Prism adaptation to leftward optical deviation (3 min duration)
Number of subjects: 15
Study 11413004 — intervention group
Group type: COMPARATOR
Intervention: Neutral prisms (3 min duration)
Number of subjects: 15
Study 9007666 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg administered before CPB commencement (group MP)
Number of subjects: 16
Study 9007666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 16
Study 8215522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 398
Study 8215522 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 398
Study 2960478 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40
Study 2960478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31838046 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut exposure during double-blind, placebo-controlled peanut challenges
Number of subjects: 0
Study 31838046 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut exposure
Number of subjects: 0
Study 29536338 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 44
Study 29536338 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 44
Study 29536338 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide 0.25 mg
Number of subjects: 44
Study 27310479 — intervention group
Group type: EXPERIMENTAL
Intervention: Crazy Taxi videogame
Number of subjects: 0
Study 27310479 — intervention group
Group type: COMPARATOR
Intervention: Insight brain training game
Number of subjects: 0
Study 24441673 — intervention group
Group type: COMPARATOR
Intervention: Topically applied tazarotene for BCC chemoprevention
Number of subjects: 70
Study 24441673 — intervention group
Group type: COMPARATOR
Intervention: Topically applied tazarotene for chemotherapy of BCC lesions
Number of subjects: 70
Study 23613639 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon intermittent dilatation (EPBID)
Number of subjects: 206
Study 23613639 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 206
Study 20646350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergoid immunotherapy (allergoid SLIT)
Number of subjects: 30
Study 20646350 — intervention group
Group type: COMPARATOR
Intervention: Standard drug therapy (Control)
Number of subjects: 30
Study 18799425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and depression
Number of subjects: 500
Study 18799425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and anxiety
Number of subjects: 500
Study 18799425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain, depression, and anxiety
Number of subjects: 500
Study 18799425 — intervention group
Group type: COMPARATOR
Intervention: Pain only
Number of subjects: 500
Study 16337781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 20
Study 16337781 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 microg
Number of subjects: 20
Study 12819076 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (45 mg elemental zinc thrice daily for 9 days starting 2 days before each vaccine dose)
Number of subjects: 30
Study 12000041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast medium
Number of subjects: 454
Study 12000041 — intervention group
Group type: COMPARATOR
Intervention: Nonionic low osmolar contrast medium
Number of subjects: 454
Study 9050361 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation
Number of subjects: 38
Study 9050361 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study 1610710 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg fusidic acid, administered twice daily for 6 days
Number of subjects: 8
Study 1610710 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg fusidic acid, administered twice daily for 6 days
Number of subjects: 8
Study 1610710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of fusidic acid
Number of subjects: 8
Study 6092554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (VAM)
Number of subjects: 147
Study 6092554 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (POCC)
Number of subjects: 147
Study 30115656 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (7 mg/m2 daily), rituximab (375 mg/m2 cycle 1 and 500 mg/m2 cycles 2-6), and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) for 6 cycles followed by 10 mg lenalidomide monotherapy for 6 months (induction-I and induction-II)
Number of subjects: 53
Study 30172196 — intervention group
Group type: EXPERIMENTAL
Intervention: Active filtration for 2 weeks
Number of subjects: 35
Study 30172196 — intervention group
Group type: COMPARATOR
Intervention: Sham filtration for 2 weeks
Number of subjects: 35
Study 26843153 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 28 days during antimalarial treatment
Number of subjects: 239
Study 26843153 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation during antimalarial treatment
Number of subjects: 239
Study 26167945 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus personalized feedback (brief motivational interventions; BMI)
Number of subjects: 133
Study 26167945 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized personalized feedback intervention (electronic check‐up to go; e‐CHUG)
Number of subjects: 133
Study 26167945 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 133
Study 26167945 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and e‐CHUG
Number of subjects: 133
Study 22476807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 162
Study 22476807 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 162
Study 20100748 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Care (FC)
Number of subjects: 366